Heart failure and transplantation with Dr Ileana Piña

ESC 2021 AVANTI: Could a 'Vaptan' Replace Loop Diuretics in Acute HF? Ileana Piña and investigator James Udelson discuss the phase 2 AVANTI trial presented at ESC on a novel 'vaptan' drug.
Experts And Viewpoints, September 17, 2021
ESC 2021 Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context Javed Butler discusses the details of the trial on empagliflozin in HFpEF with Ileana Piña and what might be learned from the subgroup analyses.
Experts And Viewpoints, August 31, 2021
ESC-HFA 2021 Can We Agree on a Universal Definition of Heart Failure? Ileana Piña speaks with Professor Andrew Coats about the universal definition of heart failure and upcoming guidelines from the Heart Failure Association of the European Society of Cardiology.
Experts And Viewpoints, July 22, 2021
ACC 2021 REHAB-HF Lays Groundwork for Recovery of Function Post HF Ileana Pina speaks with Dalane Kitzman about a tailored strategy of physical rehabilitation to improve balance, strength, mobility, and endurance after acute HF.
Experts And Viewpoints, May 24, 2021
ACC 2021 Sacubitril/Valsartan: Trending Toward PARADISE Post MI? PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key: 'Start the drug early and sustain it,' he tells Ileana Pina.
Experts And Viewpoints, May 19, 2021
What to Know About New Hypertension Guidelines in CKD Dr Ileana Piña asks Dr Peter A. McCullough what physicians need to know about heart failure and kidney disease, and the new hypertension guidelines in chronic kidney disease.
Experts And Viewpoints, April 13, 2021
HFpEF: Do We Really Know What It Is? Ileana Piña discusses phenotypes of patients with heart failure with preserved ejection fraction in the context of recent data from PARAGON-HF.
Experts And Viewpoints, March 29, 2021
When the Patient Is the Best Practice Alert: EPIC-HF Helping patients be proactive before their cardiology appointments can facilitate better management of HFrEF, says Larry Allen, lead author of EPIC-HF.
Experts And Viewpoints, January 11, 2021
Hispanics and CVD: Country of Origin Matters Hispanic, Latino -- the lingo and migratory patterns have changed over time, which is why clinicians should not assume that all patients share the same risk profiles, cautions Ileana Piña, MD.
Experts And Viewpoints, September 22, 2020
ESC 2020 SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context Dr Ileana Piña asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.
Experts And Viewpoints, August 31, 2020
Cookbook Medicine Won't Cut It With New Drugs for HFrEF The plethora of new drugs means one size will not fit all patients with HFrEF. Clinicians will have to tailor their strategies, says Ileana Pina, MD.
Experts And Viewpoints, August 20, 2020
Clinical Trials and the COVID-19 Conundrum The pandemic has critically altered current clinical research. Dr Ileana Pina implores researchers to work together and 'not stop all the good work that is being done.'
Experts And Viewpoints, June 01, 2020
VICTORIA PIs See Vericiguat as 'A Win' for High-Risk HFrEF Ileana Piña gets the details on vericiguat, an investigational guanylate cyclase stimulator that may open up a new treatment pathway for high-risk heart failure.
Experts And Viewpoints, May 13, 2020
Is Hyperkalemia Always Bad in Patients With HF? Dr Ileana Piña discusses facilitating RAAS inhibitors with potassium binders for patients with renal dysfunction.
Experts And Viewpoints, March 12, 2020
Do More HF Drugs Make It the Best or the Worst of Times? New HF treatment regimens keep piling new drugs onto the old ones, making it less likely that patients will be able to adhere to the regimen, says Dr Ileana Piña.
Experts And Viewpoints, March 03, 2020
Controversies in Cardiogenic Shock Dr Ileana Piña discusses controversies surrounding cardiogenic shock, including data presented at the AHA Scientific Sessions 2019.
Experts And Viewpoints, January 23, 2020
Making Room for New Drugs for Heart Failure Drs Ileana Piña and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.
Experts And Viewpoints, November 26, 2019
PROVE-HF Cracks the 'Holy Grail' of Cardiac Remodeling in HFrEF Ileana Piña, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.
Experts And Viewpoints, October 07, 2019
PARAGON-HF: Is There a Role for the ARNI in HFpEF? Ileana Piña quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients with HFpEF, including exploratory subgroup analyses and use of mineralocorticoid-receptor antagonists.
Experts And Viewpoints, September 16, 2019
Do We Need to Rethink Acute Heart Failure? Patients with acute heart failure may comprise more than one single group, says Dr Piña.
Experts And Viewpoints, July 19, 2019

No Results